换用阿立哌唑对精神分裂症患者代谢的影响

目的:探讨换用阿立哌唑治疗后精神分裂症患者各项代谢指标的改善情况。方法:选择43例换用阿立哌唑治疗的精神分裂症患者,分别在换药前和换药12周对患者的血糖、血脂和体质量等代谢指标进行检测。结果:换用阿立哌唑12周,患者的体质量(t=3.38,P<0.01)和体质量指数(t=3.07,P<0.01)显著改善,空腹血糖(t=2.96,P<0.01)、2h血糖(t=2.58,P<0.01)、糖化血红蛋白(t=3.50,P<0.01)、空腹胰岛素(t=19.71,P<0.01)、和稳态模型评估的胰岛素抵抗系数(t=2.70,P<0.05)均较治疗前显著降低,总胆固醇(t=2.78,P<0.01)、三酰甘油(t=4.38,P<0.01)和低密度脂蛋白(t=2.81,P<0.01)亦有显著降低,代谢综合征的患病率(χ2=19.07,P<0.01)显著降低。结论:换用阿立哌唑治疗对精神分裂症患者的代谢有显著改善作用。

Metabolic effects in treating schizophrenia patients after switching to aripiprazole

Objective:To evaluate extensively the metabolic improvements of switching to aripirzazole in the treatment of schizophrenia.Method:43 patients who had successfully switched to aripirazole with a schizophrenia diagnosis went through an extensive metabolic evaluation,including blood glucose,blood lipids and body weight test at baseline and at 12 weeks post switch.Results:There was significant decreases in body weight(t=3.38,P<0.01),body mass index(t=3.07,P<0.01),fasting glucose(t=2.96,P<0.01),glucose at 2 h(t=2.58,P<0.01),glycated hemoglobin(t=3.50,P<0.01),fasting insulin(t=19.71,P<0.01),insulin resistance index(t=2.70,P<0.05),total cholesterol(t=2.78,P<0.01),triglycerides(t=4.38,P<0.01) and low-density lipoprotein(t=2.81,P<0.01) levels.There was also a significant reduction in the prevalence of metabolic syndrome(χ2=19.07,P<0.01).Conclusion:Switching to aripiprazole can significantly improve metabolic abnormalities in treating schizophrenia.